share_log

B. Riley Securities Reiterates Buy on Journey Medical, Maintains $6 Price Target

Benzinga ·  Mar 30, 2023 21:25

B. Riley Securities analyst Kalpit Patel reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $6 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment